Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. - Wikidata - awgldk - TriplyDB

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.

http://www.wikidata.org/entity/Q36613394

about

Teriflunomide for multiple sclerosis Teriflunomide for multiple sclerosis Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis.Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.Treating multiple sclerosis with monoclonal antibodies: a 2013 update.No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.Role of oral teriflunomide in the management of multiple sclerosis.Hospitalization rates and discharge status in multiple sclerosis Teriflunomide in relapsing multiple sclerosis: therapeutic utility Teriflunomide: a review of its use in relapsing multiple sclerosis.Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.Teriflunomide: a novel oral treatment for relapsing multiple sclerosis.Teriflunomide for the treatment of relapsing-remitting multiple sclerosis.Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.Intervening to reduce the risk of future disability from multiple sclerosis: are we there yet?Teriflunomide for multiple sclerosis in real-world setting.Teriflunomide in multiple sclerosis: an update.The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multip Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials.Teriflunomide attenuates immunopathological changes in the dark agouti rat model of experimental autoimmune encephalomyelitis.Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments.The tension between early diagnosis and misdiagnosis of multiple sclerosis.The neuroprotective effect of mesenchymal stem cells on an experimentally induced model for multiple sclerosis in mice.Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.

P2860

Q24186016-1817C7C2-5C91-4FAC-ADDA-D149666EB0F5 Q24202177-A509C2B8-B7B5-471F-949C-3655A03A7C35 Q30354658-A6D86C59-8FD6-478F-80E6-2F66EDAF68FA Q30659100-3C94819B-E72C-4D24-8A9D-0F667CE119EC Q34330211-68C10C5A-00A3-45E7-8621-6D35AB00A52E Q34577661-706DBA30-8AC6-451D-A3DF-5406C59B38F6 Q36803649-16A8FE48-7A31-4AE0-9BB3-ABD77221483F Q36882707-BADD1E97-D50F-46C2-9019-D1EC9BDDFA08 Q37117605-30A022CC-7638-4DCA-942A-AFA62200EF8D Q38160410-D87E1B0B-2780-4421-9635-30D881260E4E Q38172961-CA4E4D34-F261-4BA6-9B7A-F63B8A8EE76A Q38205268-274C04B3-E850-47DB-B977-C615C8CC5909 Q38289353-26618AE0-2427-45E7-A312-48186A45ABFB Q38364965-989A953D-E10B-4C20-AA21-E47860C9D8D4 Q38777286-B5143B9E-4129-4883-97CC-940DCA8DD3AF Q38891855-8D0B0BD6-1276-4CE6-BDCC-DAA42D0E4D0A Q39114065-A0087850-15CB-42DB-8270-CEE5A5B1E60F Q39195628-3EE1AA7E-B941-45A1-92BC-A6D14DBAEE1F Q41197212-ED81E52F-20EB-4CE3-A2F4-1E4FFE16A05E Q41877062-0A882C4E-F6F0-45D8-ADD6-2D03F590663E Q46760321-DFE75CE8-11B9-4DC0-94ED-0128BFEAF4A4 Q47200732-B8C8E16C-0EAC-4181-B369-8304934C5A44 Q47800390-FE3AE230-C916-44EB-8DD9-13F4D9A74164 Q48359339-08A5FB69-1332-4C5D-8111-D29DF1A0ED35 Q53326795-390878E9-14F8-41B5-A8CD-AF3DDAE23F31

P2860

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.

http://www.wikidata.org/entity/Q36613394

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Pre-specified subgroup analyse ...... relapsing multiple sclerosis.

@ast

Pre-specified subgroup analyse ...... relapsing multiple sclerosis.

@en

type

label

Pre-specified subgroup analyse ...... relapsing multiple sclerosis.

@ast

Pre-specified subgroup analyse ...... relapsing multiple sclerosis.

@en

prefLabel

Pre-specified subgroup analyse ...... relapsing multiple sclerosis.

@ast

Pre-specified subgroup analyse ...... relapsing multiple sclerosis.

@en

P1433

Q36613394-53F08D39-4322-4EF7-B007-680C1739B320

P1476

Q36613394-102D6031-E0BF-4B7A-B09B-C3D86240EC95

P2093

Q36613394-0FA5AE40-E50E-49DE-A3C5-3B5BDAC3E695

Q36613394-3906BB01-28B3-47BD-A392-62C246DCE858

Q36613394-3D0CA83A-F88B-46E3-8497-5D49AB7D0736

Q36613394-567D5ED0-E876-4BAC-BBF9-08CA727D6E8A

Q36613394-C1DFCB75-95C8-4ADF-A7F1-E43715E146FA

Q36613394-CA53FF50-8496-4FFE-98DE-ACD0C872039E

Q36613394-D1099E4D-735B-4F44-BB9E-1C69209109E9

Q36613394-E12B5703-FFA0-42DE-94F5-9805E6415799

Q36613394-E371D324-72D5-43E2-B727-B819A0E43C08

Q36613394-FE7C2987-9422-4D3A-9EF1-B39B0485EC43

P2860

Q36613394-26338D4B-5579-4927-9A38-FCB3B7DA9662

Q36613394-39393FE5-1274-4453-A8B6-C35C63CFAA3B

Q36613394-4E023B5D-EDC4-4F0A-B7CB-8E798C408585

Q36613394-98502F5C-F61D-4408-9DF7-A92196BABE58

Q36613394-B1008F90-9659-47DB-8E94-3F5557CE0E56

Q36613394-C04CE784-8173-4325-BE4B-F9BBDCC9A0DB

Q36613394-FA4E6017-2304-4FF4-8C29-185CE76146F9

Q36613394-FBE08B2C-4B2C-4385-86FB-DCA5384E2A22

P304

Q36613394-646BC530-AB7A-4FB5-A4D3-6CB26111A187

P31

Q36613394-86A4B794-F1F8-426F-AE18-C6C643CDCB09

P356

Q36613394-AD184F96-0E69-4887-84C8-959B377DD306

P433

Q36613394-DF3594B5-3ABF-4E02-BCC8-AC82B6E98BD2

P478

Q36613394-5341AE57-C58A-477C-8F68-2D4B816D84B5

P50

Q36613394-384823C0-8FCA-4069-9B2C-B2CD5B610E5E

Q36613394-92A40517-025D-40E3-AB36-7B99B27D4BBE

P577

Q36613394-403CFED8-DD44-4DDF-828B-76898B2AC550

P5875

Q36613394-4410F2F0-64A3-4539-9DFA-8C115CC0D5AA

P698

Q36613394-68B194FA-745A-4CE4-AED0-B7BDF1D90C83

P921

Q36613394-1EC00C50-DD88-42CC-9AC3-5AC5EC211D70

Q36613394-6A699209-BB90-4E7F-97C7-7BF9DBF33879

Q36613394-9906AF44-C905-4D2A-8F83-27F8571A67E1

Q36613394-EC5EF514-FBC4-4EF4-A589-2AD042C7E37B

P932

Q36613394-B5B26055-2536-4EC7-8838-D10464F01CA2

P356

1352458512450354

P1433

Multiple Sclerosis Journal

P1476

Pre-specified subgroup analyse ...... relapsing multiple sclerosis.

@en

P2093

Aaron E Miller

http://www.w3.org/2001/XMLSchema#string

Christian Confavreux

http://www.w3.org/2001/XMLSchema#string

Jerry S Wolinsky

http://www.w3.org/2001/XMLSchema#string

Laura D'Castro

http://www.w3.org/2001/XMLSchema#string

Lin Wang

http://www.w3.org/2001/XMLSchema#string

Mark S Freedman

http://www.w3.org/2001/XMLSchema#string

Paul O'Connor

http://www.w3.org/2001/XMLSchema#string

Philippe Truffinet

http://www.w3.org/2001/XMLSchema#string

Teriflunomide Multiple Sclerosis Trial Group

http://www.w3.org/2001/XMLSchema#string

Tomas P Olsson

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study.

Review of teriflunomide and its potential in the treatment of multiple sclerosis.

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis--preliminary results.

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

P304

1625-1632

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1352458512450354

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227858011

http://www.w3.org/2001/XMLSchema#string

P698

22723573

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

multiple sclerosis

P932

3573676

http://www.w3.org/2001/XMLSchema#string